Pavle Repovic, MD, PhD

Pavle Repovic, MD, PhD

Pavle Repovic, MD, PhD
Specialty

Multiple Sclerosis, Neurology

Clinical Interests / Special Procedures Performed

Autoimmune Disorders, Clinical Research & Educ., Clinical Trials, Double Vision, Immunology, Limb Numbness, Multiple Sclerosis, Multiple Sclerosis Clinics at SNI, Neuroimmunology, Swedish Neuroscience Institute

  • Accepting Children: Unknown
  • Accepting New Patients: Yes
  • Accepting Medicare: Yes
  • Accepting Medicaid/DSHS: Yes
Payment Methods Accepted:

Bill insurance, Cash, Check, MasterCard, Payment plan, Sliding fee scale, Visa

Insurance Accepted:

Contact this office for accepted insurance plans.

Additional Information:

““Dr. Repovic was voted "Top Doctors" in Seattle Metropolitan Magazine (2011, 2012)

Nearly 4,500 physicians, nurses and physician assistants in King, Kitsap and Snohomish counties nominated colleagues they would choose to treat themselves and their loved ones.

News Release

Philosophy of Care

Offering my patients the guidance and support to effectively manage their condition and lead a fuller life

Personal Interests

foreign languages, cultures and cuisine; tango; nature

Medical School

University of Alabama School of Medicine

Residency

Cornell - New York Presbyterian Hospital

Fellowship(s)

Mount Sinai Hospital, New York

Board Certifications

American Board of Psychiatry and Neurology

Languages:

English, Serbo-Croatian, Spanish

Professional Associations:

Diplomate, American Board of Psychiatry and Neurology; Member, American Academy of Neurology

Awards:

Sylvia Lawry Fellowship (2008-2010, National MS Society); Young Investigator Fellowship (2002, International Society for Neurochemistry)

Additional Information:

““Dr. Repovic was voted "Top Doctors" in Seattle Metropolitan Magazine (2011, 2012)

Nearly 4,500 physicians, nurses and physician assistants in King, Kitsap and Snohomish counties nominated colleagues they would choose to treat themselves and their loved ones.

News Release

Peer-reviewed original contributions:
1) Repovic P, Lublin F (2010) Treatment of multiple sclerosis exacerbations. Neurol Clinics North America, in press.
2) Repovic P, Fears C, Gladson CL, Benveniste EN (2003) Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 22(50), 8117-24.
3) Repovic P, Mi K, Benveniste EN (2003) Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha and bacterial LPS. Glia 42(4), 433-46.
4) Repovic P, Benveniste EN (2002) Prostaglandin E2 is a novel inducer of Oncostatin M expression in macrophages and microglia. J Neurosci 22(13), 5334-43.
5) Van Wagoner NJ, Choi C, Repovic P, Benveniste EN (2000) Oncostatin M regulation of interleukin-6 expression in astrocytes: biphasic regulation involving the mitogen-activated protein kinases ERK1/2 and p38. J Neurochem 75(2), 563-75.
6) Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN (1999) IL-6 production by astrocytes:autocrine regulation by IL-6 and soluble IL-6 receptor. J Neurosci 19(13), 5236-44.
7) Waddel TG, Repovic P, Melendez-Hevia E, Heinrich R, Montero F (1997) Optimisation of glycolysis: a new look at the efficiency of energy coupling; Biochem Educ 25(4), 204-205.


Books and Chapters:
• Repovic P. Molecular Neurobiology and Neurotrauma chapters in the 2006 Psychiatry In-Review Study Guide, ed. S. J. Ferrando, ETAS. New York, 2006

MS Research Update: New MS tests could improve predictions of cognitive impairment

Cognitive dysfunction in multiple sclerosis (MS) is a recognized, but poorly understood phenomenon. Detection of cognitive dysfunction is hampered by the fact that cognitive testing is often long, sometimes costly and at times frustrating for patients. A brief, acceptable screening tool for cognitive dysfunction in MS is lacking.

A new study shows potential progress toward such a tool. Authors of a paper published in the Multiple Sclerosis Journal describe a 10-minute battery of computerized tests that was able to identify with fairly good sensitivity those patients who experienced cognitive impairment. This study, like several other similar efforts, awaits verification before they are more broadly accepted. It is hoped that such tools will come at no or minimal cost to the patients.

Identifying cognitive dysfunction early may be important because, according to a second study published in Neurology, early treatment is more likely to ...

Read more...

Posted on 5/14/2013 in research, MS, multiple sclerosis, neuroscience, Neuroscience Institute, MS Center, cognition | Comments (0)

Swedish Contributes to New Treatment Option for Multiple Sclerosis

 On September 12, 2012, the Food and Drug Administration (FDA) approved teriflunomide for the treatment of multiple sclerosis (MS). Teriflunomide (AUBAGIO) is a once-daily pill for the treatment of relapsing forms of MS. Led by Dr. Lily Jung Henson, the Swedish Neuroscience Institute was among several clinical sites that tested the drug. Results of the research showed that teriflunomide can lessen MS disease activity. Specifically, it behaves similarly to injectable therapies by slowing MS relapse frequency, the rate of disability and MRI activity.

The safety profile, however, is more challenging than ....

Read more...

Posted on 9/18/2012 in SNI, MS, multiple sclerosis, treatment, Neuroscience Institute, MS Center | Comments (0)

Expecting the Best in Pregnancy and Multiple Sclerosis

Considering that multiple sclerosis (MS) affects primarily women of childbearing age, it comes as no surprise that for many patients MS and pregnancy often occur together. The issues to consider when discussing pregnancy and MS include:

  • How pregnancy affects MS
  • How MS affects pregnancy
  • How MS treatment should be managed throughout pregnancy

The Pregnancy in MS (PRIMS) study of 254 patients revealed that pregnancy is generally protective against MS relapses, in particular during the third trimester. In contrast, the same study found a rebound of relapses during three months post delivery, with 30 percent of women experiencing a relapse within three months after delivery. Several strategies have been proposed to avert the risk of postpartum relapse, including the use of prophylactic IVIG or corticosteroids. More recently, exclusive breast-feeding has been found to offer some protection against postpartum MS activity; however, this finding was disputed in a subsequent study.

There is no evidence ...

Read more...

Posted on 5/16/2011 in SNI, multiple sclerosis, pregnancy | Comments (1)

Results 1-3 of 3
  • 1

Offices

Multiple Sclerosis Center
1600 East Jefferson
A Level
Seattle, WA 98122
Phone: 206-320-2200
Fax: 206-320-2560

Map & Directions

Neuroscience Institute Administrative Office
550 17th Avenue
Suite 500
Seattle, WA 98122
Phone: 206-320-2800
Fax: 206-320-2827
8 a.m. - 4:30 p.m.

Map & Directions

Physicians: Is this your profile? Click here for info

Affiliations

This provider is affiliated with:

  • Print